Exarafenib
Exarafenib (RAF/KIN_2787) is an orally-available, selective pan-RAF inhibitor. Exarafenib is effective in RAF-dependent cancers, including all classes of BRAF alterations. Exarafenib suppresses MAPK signaling in RAF-dependent melanoma cell lines. Exarafenib has anticancer activity[1][2].
Product Specifications
CAS Number
2639957-39-2
Product Name Alternative
RAF/KIN_2787
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
P38 MAPK; Raf
Type
Reference compound
Related Pathways
MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/exarafenib.html
Purity
99.68
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC1=CC=C(NC(N2C[C@@H](CC2)CC(F)(F)F)=O)C=C1C3=CC(N[C@H](C)CO)=NC(N4CCOCC4)=C3
Molecular Formula
C26H34F3N5O3
Molecular Weight
521.58
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
P38 MAPK; Raf
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Ashbya gossypii UPF0508 protein AEL141W (AEL141W), partial
